论文部分内容阅读
早在1957年,甲硝唑就用于治疗毛滴虫病。1960年开始用于治疗阿米巴病和贾第虫病。1962年发现甲硝唑有抗厌氧菌活性,其应用范围又扩大到治疗脆弱类杆菌等厌氧菌引起的感染。1978年甲硝唑已被WHO遴选为抗厌氧微生物及抗阿米巴的基本药物。1980年美国FDA正式批准甲硝唑及其注射液可治疗敏感厌氧微生物引起的感染。由于甲硝唑注射液疗效显著,抗厌氧菌谱广,耐药性少,给药后易吸收和分布,副反应少,所以它是一种极有发展前途的抗厌氧微生物药物。甲硝唑注射液在临床应用过程中,如在脓
As early as 1957, metronidazole was used to treat trichomoniasis. Beginning in 1960 for the treatment of amoebiasis and giardiasis. Metronidazole was found in 1962 anti-anaerobic activity, its scope of application has been extended to the treatment of Bacteroides fragilis and other anaerobic infections. 1978 metronidazole has been selected by WHO as anti-anaerobic microorganisms and anti-amoebasic drugs. 1980 US FDA formally approved metronidazole and its injection can treat infections caused by sensitive anaerobic microorganisms. Because metronidazole injection has significant curative effect, broad anti-anaerobic spectrum, low resistance, easy absorption and distribution after administration, and less side effects, it is a promising anti-anaerobic microorganism drug. Metronidazole injection in the clinical application process, such as in pus